10-Q/A: Envoy Medical Restates Q3 2023 Financials Due to Accounting Error

Envoy Medical has restated its third-quarter 2023 financial statements due to an error in the accounting treatment of a forward purchase agreement.

Summary

• Envoy Medical has filed an amended quarterly report to restate its financial statements for the period ended September 30, 2023.
• The restatement was necessary due to an error in the accounting treatment of a forward purchase agreement, specifically regarding the classification of a prepayment amount.
• The prepayment of $2.4 million was incorrectly classified as an asset instead of an equity transaction.
• The remaining balance of the prepaid forward contract, including a put option and maturity consideration, was incorrectly netted with the prepayment amount and presented as a net asset, instead of being separately presented as a liability.
• The company also revised its accounting for convertible notes payable, resulting in a $14.6 million downward adjustment and a $14.7 million upward adjustment in additional paid-in capital.
• Additionally, $0.3 million of expenses previously included in the cost of goods sold have been reclassified to research and development.
• The company reported a net income of $1.6 million for the three months ended September 30, 2023, and a net loss of $25.0 million for the nine months ended September 30, 2023.
• As of September 30, 2023, the company had cash of $7.4 million and an accumulated deficit of $251.0 million.

Sentiment

Score: 4

Explanation: The document reveals significant issues including a restatement due to accounting errors and material weaknesses in internal controls, which are major concerns for investors. While there are some positives such as the merger completion and increased cash balance, the overall tone is negative due to the financial and control issues.

Positives

• The company reported a net income of $1.6 million for the three months ended September 30, 2023.
• The company completed a merger transaction on September 29, 2023, which provided $11.7 million in proceeds.
• The company's cash balance increased significantly to $7.4 million as of September 30, 2023, compared to $0.2 million at the end of 2022.

Negatives

• The company had to restate its Q3 2023 financials due to an accounting error.
• The company reported a net loss of $25.0 million for the nine months ended September 30, 2023.
• The company has an accumulated deficit of $251.0 million as of September 30, 2023.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• The company is subject to risks related to the development and regulatory approval of its Acclaim cochlear implant.
• The company faces competition in the medical device industry.
• The company's financial performance is impacted by macroeconomic conditions.
• The company has identified material weaknesses in its internal control over financial reporting.

Future Outlook

The company expects to continue to incur net losses for the foreseeable future and anticipates that its research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. The company anticipates obtaining FDA approval for the Acclaim in mid-2026.

Management Comments

• Management believes that its existing cash balances combined with future capital raises, and cash receipts from product sales will be sufficient to fund ongoing operations through at least one year from the date the unaudited condensed consolidated financial statements are issued.
• Management has concluded that the error identified for restatement is consistent with the existing material weaknesses in the Company's internal control over financial reporting that existed as of September 30, 2023.

Industry Context

The company operates in the hearing health industry, focusing on innovative medical technologies. The company's Acclaim cochlear implant is designed to address severe to profound sensorineural hearing loss, a market with established acceptance and reimbursement pathways. The company's fully implanted technology is designed to leverage the natural anatomy of the ear instead of a microphone to capture sound, which is a unique approach in the industry.

Comparison to Industry Standards

• Envoy Medical's focus on fully implanted hearing devices differentiates it from competitors who primarily offer traditional hearing aids or cochlear implants with external components.
• The company's Esteem device, while not commercially successful, provides nearly two decades of experience with implantable sensor technology, a unique advantage.
• The Acclaim cochlear implant, with its fully implanted design and sensor technology, aims to disrupt the existing cochlear implant market, which is dominated by companies like Cochlear Limited and Advanced Bionics.
• Unlike some competitors, Envoy's technology is designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
• The company's financial results, particularly the net loss and accumulated deficit, are not uncommon for companies in the medical device industry that are in the development stage and require significant investment in research and development.

Legal Proceedings

• The company is involved in a lawsuit filed by Atlas Merchant Capital SPAC Fund I LP, alleging breach of the company's charter and fiduciary duty.
• The company believes the claims asserted in the lawsuit to be without merit and intends to vigorously defend the litigation.

Related Party Transactions

• The company leases its headquarters office space from a stockholder, which is considered a related party.
• The company received several loan financings from stockholders between 2012 to 2023.
• The company recorded a payable to a stockholder of $4.0 million on the condensed consolidated balance sheets as of September 30, 2023.

Stakeholder Impact

• Shareholders are impacted by the restatement of financial statements and the identified material weaknesses in internal control.
• Employees may be impacted by the company's efforts to remediate internal control weaknesses and the potential for future capital raises.
• Customers and patients may be impacted by the company's ability to successfully develop and commercialize the Acclaim cochlear implant.
• Creditors may be impacted by the company's ability to raise additional capital and its overall financial health.

Next Steps

• The company will continue its research and development efforts for the Acclaim product candidate, including through clinical trials.
• The company will seek additional regulatory and marketing approvals in jurisdictions outside the United States.
• The company will establish a sales, marketing and distribution infrastructure to commercialize its product candidate.
• The company will seek to maintain, protect, and expand its intellectual property portfolio.
• The company will seek to identify, hire, and retain additional skilled personnel.
• The company will create additional infrastructure to support its operations as a public company and its product candidate development and planned future commercialization efforts.
• The company will implement a plan to remediate the material weaknesses in internal control over financial reporting.

Key Dates

Keywords

restatement, forward purchase agreement, accounting error, convertible notes, financial statements, internal control, cochlear implant, medical device, merger, Acclaim